SCHEMBL2825249

SCHEMBL2825249

O=C(c1ccco1)N(CCCN1CCCCCC1)c1nc(-c2ccccc2)cs1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 10/20 0.71
SMN1; SMN2 Q16637 5/20 0.71
MAPT P10636 4/20 0.71
USP2 O75604 4/20 0.71
MAPK1 P28482 3/20 0.71
NPSR1 Q6W5P4 3/20 0.71
KDM4E B2RXH2 3/20 0.71
HSD17B10 Q99714 2/20 0.71
LMNA P02545 5/20 0.68
ALDH1A1 P00352 5/20 0.60
RAD52 P43351 4/20 0.59
KMT2A Q03164 8/20 0.58
MEN1 O00255 6/20 0.58
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
HPGD P15428 2/20 0.51
ALOX15 P16050 1/20 0.51
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2828628 0.92 TSHR (0.84) TSHRSMN1; SMN2MAPTUSP2MAPK1
SCHEMBL2830229 0.92 TSHR (0.73) TSHRSMN1; SMN2MAPTUSP2MAPK1
SCHEMBL2829227 0.90 MAPK1 (0.85) TSHRSMN1; SMN2MAPTUSP2MAPK1
SCHEMBL2827583 0.89 MAPK1 (0.86) TSHRSMN1; SMN2MAPTUSP2MAPK1
SCHEMBL2824812 0.86 KMT2A (0.56) TSHRSMN1; SMN2MAPTUSP2MAPK1
SCHEMBL2826474 0.85 TSHR (0.73) TSHRSMN1; SMN2MAPTUSP2MAPK1
SCHEMBL2830297 0.85 TSHR (0.64) TSHRSMN1; SMN2MAPTUSP2MAPK1
SCHEMBL2826872 0.83 SMN1; SMN2 (0.69) TSHRSMN1; SMN2MAPTUSP2MAPK1
SCHEMBL2830875 0.83 MAPK1 (0.85) TSHRSMN1; SMN2MAPTUSP2MAPK1
SCHEMBL2829586 0.82 TSHR (0.69) TSHRSMN1; SMN2MAPTUSP2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795290-B2 2-amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof GENENTECH, INC. (US) 2010-09-14 US claimed
EP-2168578-A2 2-Amido-Thiazole-Based Compounds Exhibiting ATP-Utilizing Enzyme Inhibitory Activity, and Compositions, and Uses Thereof Genentech, Inc. (US) 2010-03-31 EP claimed
US-20090048313-A1 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF GENENTECH, INC. (US) 2009-02-19 US claimed
US-7410988-B2 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof GENENTECH, INC. (US) 2008-08-12 US claimed
EP-2620150-A2 2-Amido Thiazole Based Inhibitors of ATP-Utilizing Enyzmes Genentech, Inc. (US) 2013-07-31 EP disclosed
US-7795290-B2 2-amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof GENENTECH, INC. (US) 2010-09-14 US disclosed
EP-2168578-A2 2-Amido-Thiazole-Based Compounds Exhibiting ATP-Utilizing Enzyme Inhibitory Activity, and Compositions, and Uses Thereof Genentech, Inc. (US) 2010-03-31 EP disclosed
US-20090048313-A1 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF GENENTECH, INC. (US) 2009-02-19 US disclosed
US-7410988-B2 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof GENENTECH, INC. (US) 2008-08-12 US disclosed
US-20060052416-A1 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof SQUARE 1 BANK 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048313-A1 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF ATP5ME, ATP5MG, ATP5MK TSHR 2723/4885SMN1; SMN2 4020/4885MAPT 3561/4885
US-20060052416-A1 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof ATP5ME, ATP5MG, ATP5MK TSHR 2723/4885SMN1; SMN2 4020/4885MAPT 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.